


Food & Function

Accepted Manuscript



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

1 **Bioactivity and phytochemical characterization of *Arenaria montana* L.**

2 Eliana Pereira^{a,b,1}, Lillian Barros^{a,1}, Ricardo C. Calhella^{a,c}, Montserrat Dueñas^b, Ana
3 Maria Carvalho^a, Celestino Santos-Buelga^{b,*}, Isabel C.F.R. Ferreira^{a,*}

4
5 ^a*CIMO-Escola Superior Agrária, Instituto Politécnico de Bragança, Campus de Santa
6 Apolónia, 1172, 5301-855 Bragança, Portugal.*

7 ^b*GIP-USAL, Facultad de Farmacia, Universidad de Salamanca, Campus Miguel de
8 Unamuno, 37007 Salamanca, Spain.*

9 ^c*Centro de Química, Universidade do Minho, Campus de Gualtar 4710-057 Braga,
10 Portugal.*

11
12 ¹Both authors contributed equally.

13
14 *Authors to whom correspondence should be addressed (e-mail: iferreira@ipb.pt,
15 telephone +351273303219, fax +351273325405; e-mail: csb@usal.es; telephone +34
16 923 294537; fax +34 923 294515).

18 **Abstract**

19 The bioactivity (antioxidant and cytotoxic activities) of the aqueous and methanolic
20 extracts of *Arenaria montana* L., a plant commonly used in Portuguese folk medicine,
21 was evaluated and compared. Furthermore, the phytochemical composition was
22 determined regarding hydrophilic (sugars, organic acids and phenolic compounds) and
23 lipophilic (fatty acids and tocopherols) compounds, in order to valorize this plant
24 material as a functional food/nutraceutical. Fructose, oxalic acid, methyl-luteolin 2''-O-
25 feruloylhexosyl-C-hexoside, α -tocopherol, and linoleic acid were the main individual
26 compounds found in *A. montana*. In general, the aqueous extract gave higher
27 antioxidant and cytotoxic activity than the methanolic extract; the latter showed activity
28 only against HeLa and HepG2 cell lines. Both aqueous and methanolic extracts showed
29 some hepatotoxicity but at higher doses than the ones active for tumor cell lines.
30 Moreover, the aqueous extract of *A. montana* may be used as a functional food or
31 nutraceutical due to the high antioxidant and cytotoxic activity, and to the presence of
32 bioactive compounds. As far as we know, this is the first report on phytochemical
33 composition and bioactivity of *A. montana*.

34

35 *Keywords:* *Arenaria montana* L.; Antioxidant activity; Cytotoxicity; Phytochemicals

36 Introduction

37 The study of plants used in folk medicine has progressively increased over the last
38 decades.¹ Some of their putative therapeutic benefit arise from a diverse phytochemical
39 composition, which confers them antioxidant potential along with other bioactive
40 properties namely, anticarcinogenic/antimutagenic, antibacterial, antiviral or anti-
41 inflammatory properties.^{2,3} Among the various biologically active molecules, phenolic
42 compounds are a major contributor to the antioxidant activity of those plants.⁴⁻¹⁰ The
43 antioxidant activity of phenolic compounds is influenced by the number and position of
44 phenolic hydroxyls and other substituents, and glycosylation of the molecules.^{11,12}
45 Furthermore, antitumor properties have also been attributed to different phenolic
46 compounds, including flavones.¹³

47 Other important antioxidant molecules are tocopherols, which are considered one of the
48 most important antioxidants to combat oxidative stress, because they inhibit the
49 production of peroxy radicals, protecting cells of oxidative damage to low density
50 lipoproteins, proteins and DNA, and of membrane degeneration due to peroxidation of
51 polyunsaturated fatty acids.^{14,15} Some organic acids are also excellent antioxidants; for
52 example, ascorbic acid, being a potent reducing agent, has the capacity to reduce the
53 most reactive species of oxygen and nitrogen protecting against lipid peroxidation.¹⁶
54 The reducing sugars, due to the same capacity, could also display antioxidant activity.¹⁷

55 Different health benefits of polyunsaturated fatty acids (PUFA) have also been
56 described. For example, it was reported that PUFA could be used to sensitize breast
57 cancer cell lines and mammary tumors to anticancer drugs, increasing survival and
58 chemotherapy efficacy.^{18,19} The mentioned phytochemicals are common in medicinal
59 plants and often responsible for their bioactive effects.

60 *Arenaria montana* L. (Mountain sandwort) is an herbaceous plant native to
61 mountainous regions of southwestern Europe, being usually gathered in woodlands. The
62 infusion of the dried plant (stems, leaves and flowers) is used in Portuguese traditional
63 medicine for its anti-inflammatory and diuretic properties.^{20,21} Nevertheless, as far as we
64 know, there are no previous reports on the phytochemical composition of this plant.
65 The aim of the current study was to characterize the chemical composition of *A.*
66 *montana* and to assess the antioxidant and cytotoxic properties of their aqueous and
67 methanol extracts.

68

69 **Experimental**

70 **Sample**

71 *Arenaria montana* L. (Caryophyllaceae) flowers and leafy stems (approximately the
72 upper 15 cm of the dense clumps produced in spring) are commonly wild gathered in
73 Bragança (Northeastern Portugal). Then these plant materials are dried, prepared in
74 infusion, recommended and used as homemade remedies.²¹ Considering the availability
75 and local consumers' criteria for its medicinal use, the species was collected in full
76 bloom, in spring along paths through the oak trees, in Oleiros, Bragança. A sample for
77 analysis was made putting together the material from different plants. Voucher
78 specimens are deposited at the Herbarium of the Escola Superior Agrária de Bragança
79 (BRESA). The sample was lyophilized (FreeZone 4.5, Labconco, Kansas City, MO,
80 USA), reduced to a fine dried powder (20 mesh) and mixed to obtain homogeneity.

81

82 **Standards and Reagents**

83 Acetonitrile 99.9%, n-hexane 95% and ethyl acetate 99.8% were of HPLC grade from
84 Fisher Scientific (Lisbon, Portugal). The fatty acids methyl ester (FAME) reference

85 standard mixture 37 (standard 47885-U) was purchased from Sigma (St. Louis, MO,
86 USA), as also were other individual fatty acid isomers, L-ascorbic acid, tocopherols (α -,
87 β -, γ -, and δ -isoforms), sugars (D(-)-fructose, D(+)-sucrose, D(+)-glucose, D(+)-
88 trehalose and D(+)-raffinose pentahydrate), trolox (6-hydroxy-2,5,7,8-
89 tetramethylchroman-2-carboxylic acid), gallic acid and (+)-catechin standards. Racemic
90 tocol, 50 mg/mL, was purchased from Matreya (Plesant Gap, PA, USA). 2,2-Diphenyl-
91 1-picrylhydrazyl (DPPH) was obtained from Alfa Aesar (Ward Hill, MA, USA). Fetal
92 bovine serum (FBS), L-glutamine, hank's balanced salt solution (HBSS), trypsin-EDTA
93 (ethylenediaminetetraacetic acid), penicillin/streptomycin solution (100 U/mL and 100
94 mg/mL, respectively), RPMI-1640 and DMEM media were from Hyclone (Logan,
95 Utah, USA). Acetic acid, ellipticine, sulforhodamine B (SRB), trypan blue,
96 trichloroacetic acid (TCA) and Tris were from Sigma Chemical Co. (Saint Louis, MO,
97 USA). All other chemicals and solvents were of analytical grade and purchased from
98 common sources. Water was treated in a Milli-Q water purification system (TGI Pure
99 Water Systems, Greenville, SC, USA).

100

101 **Evaluation of bioactivity**

102 *Samples preparation.* The methanolic extract was obtained from the lyophilized plant
103 material. The sample (1 g) was extracted by stirring with 25 mL of methanol (25 °C at
104 150 rpm) for 1 h and subsequently filtered through Whatman No. 4 paper. The residue
105 was then extracted with 25 mL of methanol (25 °C at 150 rpm) for 1 h. The combined
106 methanolic extracts were evaporated at 40 °C (rotary evaporator Büchi R-210, Flawil,
107 Switzerland) to dryness.

108 The aqueous extract (infusion) was also obtained from the lyophilized plant material.

109 The sample (1 g) was added to 200 mL of boiling distilled water and left to stand at

110 room temperature for 5 min, and then filtered under reduced pressure. The obtained
111 extract was frozen and lyophilized.

112 Methanolic and aqueous extracts were redissolved in *i*) methanol and water,
113 respectively (final concentration 2.5 mg/mL) for antioxidant activity evaluation, or *ii*)
114 water (final concentration 8 mg/mL) for cytotoxicity evaluation. The final solutions
115 were further diluted to different concentrations to be submitted to distinct bioactivity
116 evaluation *in vitro* assays. The results were expressed in *i*) EC₅₀ values (sample
117 concentration providing 50% of antioxidant activity or 0.5 of absorbance in the reducing
118 power assay) for antioxidant activity, or *ii*) GI₅₀ values (sample concentration that
119 inhibited 50% of the net cell growth) for cytotoxicity. Trolox and ellipticine were used
120 as positive controls in antioxidant and cytotoxic activity evaluation assays, respectively.

121

122 *Antioxidant activity.* DPPH radical-scavenging activity was evaluated by using an
123 ELX800 microplate reader (Bio-Tek Instruments, Inc; Winooski, VT, USA), and
124 calculated as a percentage of DPPH discolouration using the formula: $[(A_{\text{DPPH}} -$
125 $A_{\text{S}})/A_{\text{DPPH}}] \times 100$, where A_{S} is the absorbance of the solution containing the sample at
126 515 nm, and A_{DPPH} is the absorbance of the DPPH solution. Reducing power was
127 evaluated by the capacity to convert Fe^{3+} into Fe^{2+} , measuring the absorbance at 690 nm
128 in the microplate reader mentioned above. Inhibition of β -carotene bleaching was
129 evaluated through the β -carotene/linoleate assay; the neutralization of linoleate free
130 radicals avoids β -carotene bleaching, which is measured by the formula: β -carotene
131 absorbance after 2h of assay/initial absorbance) $\times 100$. Lipid peroxidation inhibition in
132 porcine (*Sus scrofa*) brain homogenates was evaluated by the decreasing in
133 thiobarbituric acid reactive substances (TBARS); the colour intensity of the
134 malondialdehyde-thiobarbituric acid (MDA-TBA) was measured by its absorbance at

135 532 nm; the inhibition ratio (%) was calculated using the following formula: $[(A - B)/A]$
136 $\times 100\%$, where A and B were the absorbance of the control and the sample solution,
137 respectively.²²

138

139 *Cytotoxicity for tumor cell lines.* Five human tumour cell lines were used: MCF-7
140 (breast adenocarcinoma), NCI-H460 (non-small cell lung cancer), HCT-15 (colon
141 carcinoma), HeLa (cervical carcinoma) and HepG2 (hepatocellular carcinoma). Cells
142 were routinely maintained as adherent cell cultures in RPMI-1640 medium containing
143 10% heat-inactivated FBS (MCF-7, NCI-H460 and HCT-15) and 2 mM glutamine or in
144 DMEM supplemented with 10% FBS, 2 mM glutamine, 100 U/mL penicillin and 100
145 mg/mL streptomycin (HeLa and HepG2 cells), at 37 °C, in a humidified air incubator
146 containing 5% CO₂. Each cell line was plated at an appropriate density (7.5×10^3
147 cells/well for MCF-7, NCI-H460 and HCT-15 or 1.0×10^4 cells/well for HeLa and
148 HepG2) in 96-well plates and allowed to attach for 24 h. Cells were then treated for 48
149 h with various extract concentrations. Following this incubation period, the adherent
150 cells were fixed by adding cold 10% trichloroacetic acid (TCA, 100 μ L) and incubated
151 for 60 min at 4 °C. Plates were then washed with deionized water and dried;
152 sulforhodamine B solution (0.1% in 1% acetic acid, 100 μ L) was then added to each
153 plate well and incubated for 30 min at room temperature. Unbound SRB was removed
154 by washing with 1% acetic acid. Plates were air dried, the bound SRB was solubilised
155 with 10 mM Tris (200 μ L) and the absorbance was measured at 540 nm in the
156 microplate reader mentioned above.²³

157

158 *Hepatotoxicity.* A cell culture was prepared from a freshly harvested porcine liver
159 obtained from a local slaughter house, and it was designed as PLP2. Briefly, the liver

160 tissues were rinsed in hank's balanced salt solution containing 100 U/mL penicillin, 100
161 $\mu\text{g}/\text{mL}$ streptomycin and divided into $1 \times 1 \text{ mm}^3$ explants. Some of these explants were
162 placed in 25 cm^2 tissue flasks in DMEM medium supplemented with 10% fetal bovine
163 serum, 2 mM nonessential amino acids and 100 U/mL penicillin, 100 mg/mL
164 streptomycin and incubated at $37 \text{ }^\circ\text{C}$ with a humidified atmosphere containing 5% CO_2 .
165 The medium was changed every two days. Cultivation of the cells was continued with
166 direct monitoring every two to three days using a phase contrast microscope. Before
167 confluence was reached, cells were subcultured and plated in 96-well plates at a density
168 of 1.0×10^4 cells/well, and cultivated in DMEM medium with 10% FBS, 100 U/mL
169 penicillin and 100 $\mu\text{g}/\text{mL}$ streptomycin.²³

170

171 **Phytochemical composition in hydrophilic compounds**

172 *Sugars.* Free sugars were determined by high performance liquid chromatography
173 coupled to a refraction index detector (HPLC-RI), after an extraction procedure
174 previously described by the authors²² using melezitose as internal standard (IS). The
175 equipment consisted of an integrated system with a pump (Knauer, Smartline system
176 1000, Berlin, Germany), degasser system (Smartline manager 5000), auto-sampler (AS-
177 2057 Jasco, Easton, MD, USA) and a RI detector (Knauer Smartline 2300). Data were
178 analysed using Clarity 2.4 Software (DataApex, Prague, Czech Republic). The
179 chromatographic separation was achieved with a Eurospher 100-5 NH_2 column ($4.6 \times$
180 250 mm , 5 mm, Knauer) operating at $30 \text{ }^\circ\text{C}$ (7971 R Grace oven). The mobile phase
181 was acetonitrile/deionized water, 70:30 (v/v) at a flow rate of 1 mL/min. The
182 compounds were identified by chromatographic comparisons with authentic standards.
183 Quantification was performed using the internal standard method and sugar contents
184 were further expressed in g per 100 g of dry weight (dw).

185 *Organic acids.* Organic acids were determined following a procedure previously
186 described by the authors.²⁴ The analysis was performed using a Shimadzu 20A series
187 UFLC (Shimadzu Cooperation, Kyoto, Japan). Separation was achieved on a
188 SphereClone (Phenomenex, Torrance, CA, USA) reverse phase C₁₈ column (5 μm, 250
189 mm × 4.6 mm i.d) thermostatted at 35 °C. The elution was performed with sulphuric
190 acid 3.6 mM using a flow rate of 0.8 mL/min. Detection was carried out in a DAD,
191 using 215 nm and 245 nm (for ascorbic acid) as preferred wavelengths. The organic
192 acids found were quantified by comparison of the area of their peaks recorded at 215
193 nm with calibration curves obtained from commercial standards of each compound. The
194 results were expressed in g per 100 g of dry weight.

195

196 *Phenolic compounds.* Phenolic compounds were determined by HPLC (Hewlett-
197 Packard 1100, Agilent Technologies, Santa Clara, CA, USA) as previously described by
198 the authors.²⁵ Double online detection was carried out in a DAD using 280 nm and 370
199 nm as preferred wavelengths and in a mass spectrometer (API 3200 Qtrap, Applied
200 Biosystems, Darmstadt, Germany) connected to the HPLC system via the DAD cell
201 outlet. The phenolic compounds were characterized according to their UV and mass
202 spectra and retention times, and comparison with authentic standards when available.
203 The phenolic compounds were identified by comparing their retention time, UV-vis and
204 mass spectra with those obtained from standard solutions, when available. Otherwise,
205 peaks were tentatively identified comparing the obtained information with available
206 data reported in the literature. For quantitative analysis, a calibration curve (2.5-100
207 μg/mL) for each available phenolic standard was constructed based on the UV signal:
208 apigenin 6-*C*-glucoside ($y = 223.22x + 60.915$; $R^2=1$); luteolin 6-*C*-glucoside ($y =$
209 $508.54x - 152.82$; $R^2=0.997$). For the identified phenolic compounds for which a

210 commercial standard was not available, the quantification was performed through the
211 calibration curve of other compound from the same phenolic group. The results were
212 expressed in mg per 100 g of dry weight (dw).

213

214 **Phytochemical composition in lipophilic compounds**

215 *Fatty acids.* Fatty acids were determined by gas–liquid chromatography with flame
216 ionization detection (GC-FID)/capillary column as described previously by the
217 authors.²² The analysis was carried out with a DANI model GC 1000 instrument
218 equipped with a split/splitless injector, a flame ionization detector (FID at 260 °C) and a
219 Macherey-Nagel (Duren, Germany) column (50% cyanopropyl-methyl-50%
220 phenylmethylpolysiloxane, 30 m x 0.32 mm ID x 0.25 µm d_f). The oven temperature
221 program was as follows: the initial temperature of the column was 50 °C, held for 2 min,
222 then a 30 °C/min ramp to 125 °C, 5 °C/min ramp to 160 °C, 20 °C/ min ramp to 180 °C,
223 3 °C/min ramp to 200 °C, 20 °C/min ramp to 220 °C and held for 15 min. The carrier gas
224 (hydrogen) flow-rate was 4.0 mL/min (0.61 bar), measured at 50 °C. Split injection
225 (1:40) was carried out at 250 °C. Fatty acid identification was made by comparing the
226 relative retention times of FAME peaks from samples with standards. The results were
227 recorded and processed using the CSW 1.7 Software (DataApex 1.7, Prague, Czech
228 Republic) and expressed in relative percentage of each fatty acid.

229

230 *Tocopherols.* Tocopherols were determined following a procedure previously described
231 by the authors.²² Analysis was performed by HPLC (equipment described above), and a
232 fluorescence detector (FP-2020; Jasco, Easton, MD, USA) programmed for excitation at
233 290 nm and emission at 330 nm. The chromatographic separation was achieved with a
234 Polyamide II (250 x 4.6 mm) normal-phase column from YMC Waters operating at 30

235 °C. The mobile phase used was a mixture of n-hexane and ethyl acetate (70:30, v/v) at a
236 flow rate of 1 mL/min, and the injection volume was 20 μ L. The compounds were
237 identified by chromatographic comparisons with authentic standards. Quantification
238 was based on the fluorescence signal response of each standard, using the IS (tocol)
239 method and by using calibration curves obtained from commercial standards of each
240 compound. The results were expressed in mg per 100 g of dry weight.

241

242 **Statistical analysis**

243 For each one of the species three samples were used and all the assays were carried out
244 in triplicate. The results are expressed as mean values and standard deviation (SD). The
245 results were analyzed using one-way analysis of variance (ANOVA) followed by
246 Tukey's HSD Test with $\alpha = 0.05$. This treatment was carried out using SPSS v. 18.0
247 program.

248

249 **Results and discussion**

250 **Evaluation of antioxidant activity**

251 The results obtained in the antioxidant activity evaluation of the aqueous and
252 methanolic extracts of *A. montana* are given in **Table 1**. The aqueous extract gave
253 higher antioxidant activity than the methanolic extract in all the assays, with the
254 exception of DPPH scavenging activity assay in which both samples showed similar
255 results.

256 The effects of *A. montana* methanolic and aqueous extracts on the growth of five human
257 tumor cell lines (MCF-7, NCI-H460, HCT-15, HeLa and HepG2), represented as the
258 concentrations that caused 50% of cell growth inhibition (GI_{50}), are also summarized in
259 **Table 1**. The aqueous extract showed activity against all the tumor cell lines, while the

260 methanolic extract only presented some activity for HeLa and HepG2 cell lines. In
261 general, it may be concluded that the bioactive compounds involved in growth
262 inhibition of the other cell lines are preferentially extracted in the aqueous preparation.
263 Curiously, HeLa and HepG2 were the most susceptible (lowest GI₅₀ values) cell lines to
264 the aqueous extract. Both the aqueous and methanolic extracts showed some
265 hepatotoxicity but at high doses (332.18 µg/mL and 350.25 µg/mL, respectively).
266 However, it should be highlighted that at the doses active against tumor cell lines, the
267 aqueous extract did not show hepatotoxicity.

268 Trolox and ellipticine were used as positive controls in antioxidant and cytotoxic
269 activities evaluation assays, respectively, but comparison with the samples should be
270 avoided, because they are individual compounds and not mixtures as the studied
271 extracts.

272 To the best of our knowledge, no reports are available on the bioactivity of the aqueous
273 or methanolic extracts of the aforementioned plant.

274

275 **Composition in hydrophilic compounds**

276 The chemical composition of the samples in sugars and organic acids was also analyzed
277 and the results are shown in **Table 2**. The sugars found were fructose, glucose, sucrose
278 trehalose and raffinose, fructose being the most abundant; as a reducing sugar it has
279 antioxidant capacity.

280 Oxalic, quinic, malic, ascorbic, citric, succinic and fumaric acids were also identified
281 and quantified (**Table 2**), being oxalic and malic acids the most abundant organic acids.
282 Some of these acids (*e.g.*, ascorbic and citric acids) have been reported as having
283 antioxidant capacity and health benefits.^{26,27} Oppositely, several studies indicate that

284 oxalic acid causes acute oxalate nephropathy and neurotoxicity in humans and
285 animals.²⁸

286 Ten phenolic compounds were identified in the methanolic extract of *A. montana*
287 (flowers and leafy stems) being all of them flavone derivatives. The HPLC phenolic
288 profile recorded at 370 nm is shown in **Figure 1**, and peak characteristics, identities and
289 quantification are presented in **Table 3**.

290 Luteolin-6-*C*-glucoside (peak 3), and apigenin 6-*C*-glucoside (peak 6) were positively
291 identified according to their retention, mass and UV-vis characteristics by comparison
292 with commercial standards.

293 Peaks 2, 4 and 7 presented similar UV spectra as peak 6 with λ_{\max} at 336-338 nm,
294 suggesting that may derive from apigenin. All these peaks showed fragments ions at m/z
295 311 and 341, corresponding to the aglycone (apigenin) +41 mu and +71 mu,
296 respectively, that are characteristic of *C*-glycosylated flavones.²⁹ Peaks 2 and 4 had the
297 same pseudomolecular ion $[M-H]^-$ at m/z 563 pointing to apigenin bearing pentose and
298 hexose sugar substituents, but yielded different MS² fragment ions. According to
299 Ferreres et al.²⁹, the ions aglycone + 83 mu and aglycone + 113 mu would typify di-*C*-
300 glycosylated flavones. Thus, the observation of the ions at m/z 383 (agl+113) and 353
301 (agl+83) in the case of peak 2 would indicate that both sugars are *C*-attached, which is
302 supported by the losses of -120 mu (ion at m/z 443), -180 mu (90+90; m/z at 383), and
303 210 mu (120+90; m/z at 353), characteristic of *C*-glycosylated flavones.³⁰ The loss of -
304 120 mu is typical of *C*-attached hexoses, whereas that of -90 mu is observed for *C*-
305 attached pentoses and it is also usual in the case of 6-*C*-hexoses but less common in the
306 case of 8-*C*-hexoses.³¹ These observations allowed the tentative identification of peak 2
307 as apigenin 6-*C*-hexoside-8-*C*-pentoside.

308 The fragmentation of peak 4 would be more coherent with an *O,C*-diglycoside. The loss
309 of -120 mu leading to the ion at m/z 443 ($^{0,2}X_0^-$ in the **Figure 2**) supported the presence
310 of a *C*-attached hexose, while the absence of an ion $[(M-H)-90]^-$ pointed to a 6-*C*
311 attachment. The lack of an ion $[(M-H)-132]^-$ from the loss of the pentosyl residue
312 suggested that this sugar was not linked to the aglycone but to the other sugar; this was
313 confirmed by the presence of an abundant $[(M-H)-150]^-$ ion (Z_1^- in the **Figure 2**) at m/z
314 413, which according to Ferreres et al.²⁹ would be characteristic of an *O*-attached
315 pentose on the *C*-glycosylating hexose. The *O*-glycosylation should not take place in the
316 positions 6'', 4'' or 3'' of the hexose, otherwise the fragment $[(M-H)-120]^-$ would not
317 be produced. Finally, the ion at m/z 293 would result from the fragment at m/z 413 by
318 further loss of a fragment of 120 mu (partial loss of the *C*-attached hexose). All in all,
319 peak 4 could be tentatively identified as apigenin 2''-*O*-pentosyl-6-*C*-hexoside.

320 Peak 7 ($[M-H]^-$ at m/z 605) was 42 mu greater than peak 4 and showed similar
321 fragmentation pattern, so that it can be assigned to an acetyl derivative of peak 4. The
322 observation of an abundant ion at m/z 413 ($[(M-H)-42-150]^-$) from the loss of the
323 pentose after release of the acetyl residue would confirm that this sugar was *O*-linked to
324 the *C*-hexose. The observation of an ion at m/z 431 ($[(M-H)-42-132]^-$) might indicate
325 that the acetyl moiety is attached to the pentose. Further losses of -120 mu and -90 mu
326 from that ion suggested that the hexose was 6-*C*-attached. Thus, the peak was
327 tentatively assigned as apigenin 2''-*O*-acetylpentosyl-6-*C*-hexoside.

328 Peaks 1 and 10 would also derive from apigenin owing to the presence of the fragments
329 at m/z 311 and 341. In the case of peak 1 ($[M-H]^-$ at m/z 593) the observation of the ions
330 at m/z 473 and 353 from two consecutive losses of -120 mu would point to a di-*C*-
331 hexosyl derivative, so that it could be tentatively associated to apigenin 6-*C*-hexoside-8-
332 *C*-hexoside.

333 Peak 10 ($[M-H]^-$ at m/z 769) had a mass 176 u greater than apigenin di-hexoside
334 suggesting acylation with ferulic acid, which is coherent with its delayed elution. The
335 cleavage of the feruloyl residue yielded the ion at m/z 593, which would give rise to the
336 formation of the abundant ion at m/z 413 by loss of a fragment of 180 u, which,
337 according to Ferreres et al.²⁹, would be characteristic of an *O,C*-dihexoside. On the
338 other hand, the loss of -120 mu to produce the ion at m/z 649 confirmed the existence of
339 a hexose *C*-attached to the aglycone, and also that the feruloyl residue was linked to the
340 second *O*-attached hexose. By similarity with the other apigenin *O,C*-diglycosides
341 observed in the sample, a 6-*C* attachment might be supposed. Thus, peak 10 was
342 tentatively assigned as apigenin 2''-*O*-feruloylhexosyl-6-*C*-hexoside.

343 The fragmentation pattern of peak 5 ($[M-H]^-$ at m/z 769) would also be coherent with a
344 structure similar to peak 10 although having luteolin as aglycone. Thus, the losses of -
345 120 mu (ion at m/z 489) and -176 mu (ion at m/z 609), and further -180 mu (ion at m/z
346 429) would point to a *O,C*-dihexoside. The fragment at m/z 489 (loss of -120 mu from
347 the ion at m/z 609) would confirm the presence of the *C*-attached hexose, and the ion at
348 m/z 339 (loss of -90 mu from the ion at m/z 429) would suggest a 6-*C* attachment. Thus,
349 the peak was tentatively identified as luteolin 2''-*O*-feruloylhexosyl-6-*C*-hexoside.

350 Pseudomolecular ion of peak 9 ($[M-H]^-$ at m/z 799) was 14 mu greater than peak 5 and
351 showed similar fragmentation pattern, with characteristic product ions resulting from
352 the losses of fragments of 120 mu (ion at m/z 679), 176 mu (ion at m/z 623), 176+180
353 mu (ion at m/z 609) and 176+180+120 mu (ion at m/z 323). The observation of
354 fragments at m/z 371 (aglycone + 71 mu) and 323 (aglycone + 41-18 mu) would support
355 the presence of methyl-luteolin as aglycone.²⁹ Therefore, the compound might be
356 tentatively assigned as methyl-luteolin 2''-*O*-feruloylhexosyl-*C*-hexoside.

357 Finally, peak 8 presented a pseudomolecular ion $[M-H]^-$ at m/z 635 and fragment ions at
358 m/z 593 (-42 mu), 515 (-120 mu), indicating the presence of an acetyl residue and a C-
359 attached hexose. The abundant ion at m/z 443 by loss of a fragment of 150 mu from the
360 ion at m/z 515 would indicate the presence of an *O*-attached pentose on the C-
361 glycosylating hexose.²⁹ The fragment at m/z 461 would result from the loss of the
362 pentosyl residue (-132 mu) from the ion at m/z 515, and the ions at m/z 371 and 323
363 would also support methyl-luteolin as aglycone. Thus, the compound was tentatively
364 identified as methyl-luteolin 2''-*O*-acetylpentosyl-*C*-hexoside.

365 Methyl-luteolin 2''-*O*-feruloylhexosyl-*C*-hexoside was the main flavone found (450.26
366 mg/100 g dw) in *A. montana* (**Table 3**), being the total amount of flavones 1204.63
367 mg/100 g dw. As far as we know, there are no data regarding phenolic composition in
368 this plant, thus these values cannot be compared to literature. It should also be
369 highlighted that little is known about phenolic compound bioactive forms *in vivo*
370 (achievable concentrations in the circulation after ingestion as well as the possibility of
371 metabolism) and the mechanisms by which they may contribute toward disease
372 prevention.³²

373

374 **Composition in lipophilic compounds**

375 The results of lipophilic compounds (fatty acids and tocopherols) are shown in **Table 4**.
376 Up to 28 fatty acids were identified and quantified. Polyunsaturated fatty acids (PUFA)
377 predominated over saturated fatty acids (SFA) and monounsaturated fatty acids
378 (MUFA). Linoleic (C18:2n6) acid was the major fatty acid and contributes to the high
379 levels of PUFA observed. The interest of linoleic acid has increased over time, since it
380 is an essential fatty acid for human development and plays an active role in good
381 general health.³³ Among others, it has been shown to have a role on the prevention of

382 cancer diseases.³⁴ PUFA, besides being endogenous mediators of cell signaling and
383 being involved in regulating gene expression, are also precursors of eicosanoids, such as
384 prostaglandins and leukotrienes, as well as docosanoids as protectins or resolvins.³³
385 α -Tocopherol was the most abundant tocopherol in *A. Montana*, being also found the
386 isoforms γ - and δ -; **Table 4**). Tocopherols are very important natural antioxidants and
387 can be used to delay rancidity in fatty materials in manufactured foods; they may also
388 reduce the effects of aging and help to prevent oxidative stress-related diseases such as
389 cancer, neurodegenerative and heart diseases.^{35,36}

390

391 **Conclusion**

392 In summary, bioactive phytochemicals such as phenolic compounds and tocopherols
393 were identified and quantified in *A. montana*, as also omega-3 and omega-6 families,
394 constituting another important class of phytochemicals due to their generalised
395 beneficial health effects. The aqueous extract revealed higher antioxidant and cytotoxic
396 activities than the methanolic extract. Therefore, the aqueous extract of *A. montana* may
397 be used as a functional food, due to the high antioxidant activity, and as a nutraceutical,
398 by presenting bioactive compounds, such as flavones and tocopherols, that can be used
399 as cytotoxic agents. Moreover, this study supports the documented medicinal effect of
400 this species and opens the possibilities of food and pharmaceutical applications.

401

402 **Competing interests**

403 The authors declare no competing financial interest.

404

405 **Acknowledgements**

406 The authors are grateful to Fundação para a Ciência e a Tecnologia (FCT, Portugal) for
407 financial support to CIMO (strategic project PEst-OE/AGR/UI0690/2011), REQUIMTE
408 (PEst-C/EQB/LA0006/2011), M.I. Dias (SFRH/BD/84485/2012 grant), R.C. Calhella
409 (SFRH/BPD/68344/2010 grant) and L. Barros (contract under “Programa Compromisso
410 com Ciência-2008”). The GIP-USAL is financially supported by the Spanish
411 Government through the *Consolider-Ingenio 2010* Programme (FUN-C-FOOD,
412 CSD2007-00063). M. Dueñas thanks to the *Programa Ramón y Cajal* for a contract.

413

414 **References**

- 415 1 G. Bulut and E. Tuzlaci, *J. Ethnopharmacol.*, 2013, 149, 633–647.
- 416 2 K.T. Chung, T.Y. Wong, Y.W. Huang and Y. Lin, *Crit. Rev. Food Sci. Nutr.*, 1998,
417 38, 421–464.
- 418 3 H. Tapiero, K.D. Tew, N. Ba and G. Mathé, *Biomed. Pharmacother.*, 2002, 56,
419 200-207.
- 420 4 C.A. Rice-Evans, N.J. Miller and G. Paganga, *Free Radic. Biol. Med.*, 1996, 20,
421 933–956.
- 422 5 S. Dragland, H. Senoo, K. Wake, K. Holte and R. Blomhoff, *J. Nutr.*, 2003, 133,
423 1286-1290.
- 424 6 Y.Z. Cai, Q. Luo, M. Sun and H. Corke, *Life Sci.*, 2004, 74, 2157–2184.
- 425 7 L. Sha, L. Shu-Ke, G. Ren-You, S. Feng-Lin, K. Lei and L. Hua-Bin, *Ind. Crop.*
426 *Prod.*, 2013, 51, 289-298.
- 427 8 K. Kalantar-Zadeh, G.H. Leeb and G. Block, *Med. Hypotheses*, 2004, 62, 280–290.
- 428 9 S. Schaffer and B. Halliwell, *Genes Nutr.*, 2012, 7, 99-109.
- 429 10 V. Castel, O. Andrich, F.M. Netto, L.G. Santiago and C.R. Carrara, *J. Food Eng.*,
430 2014, 122, 62–67.

- 431 11 T. Yokozawa, C.P. Chen, E. Dong, T. Tanaka, G.-I. Nonaka and I. Nishioko,
432 Biochem. Pharmacol., 1998, 56, 213–222.
- 433 12 Y-Z. Cai, M. Sun, J. Xing, Q. Luo and H. Corke, Life Sci., 2006, 78, 2872 -2888.
- 434 13 M. Carocho and I.C.F.R. Ferreira, Anti-Cancer Agents Med. Chem. 2013, 13,
435 1236-1258.
- 436 14 Y.Z. Fang, S. Yang and G. Wu, Nutrition, 2002, 18, 872-879.
- 437 15 T.S. Kim, E.A. Decker and J., Lee, Food Chem., 2012, 133, 68-75.
- 438 16 B. Halliwell, Nutr. Rev., 2012, 70, 257–265.
- 439 17 I. Spasojević, A. Bajić, K. Jovanović, M. Spasić and P. Andjus, Carbohydr. Res.,
440 2009, 344, 1676–1681.
- 441 18 N. Hajjaji and P. Bougnoux, Cancer Treat. Rev., 2013, 39, 473–488.
- 442 19 R. Wannous, E. Bon, K. Mahéoa, C. Goupille, J. Chamouton, P. Bougnoux, S.
443 Roger, P. Besson, S. Chevalier, Biochim. et Biophys. Acta, 2013, 1831, 1618–
444 1625.
- 445 20 G. Timité, A-C. Mitaine-Offer, T. Miyamoto, C. Tanaka, J-F. Mirjolet, O.
446 Duchamp and M-A. Lacaille-Dubois, Phytochem., 2011, 72, 503–507.
- 447 21 A.M. Carvalho and R. Morales, In M. Pardo de Santayana, A. Pieroni, and R. Puri
448 (eds.), Ethnobotany in the New Europe: People. 2nd edition, Berghahn Books,
449 Oxford, UK, 2013, 147-171.
- 450 22 J. Pinela, L. Barros, A.M. Carvalho and I.C.F.R. Ferreira, Food Chem. Toxicol.,
451 2011,49, 2983-2989.
- 452 23 R. Guimarães, L. Barros, M. Dueñas, R.C. Calhelha, A.M. Carvalho, C. Santos-
453 Buelga, M.J.R.P. Queiroz and I.C.F.R. Ferreira, Food Chem., 2013, 136, 718-725.
- 454 24 L. Barros, C. Pereira and I.C.F.R. Ferreira, Food Anal. Method., 2013, 6, 309-316.

- 455 25 L. Barros, Dueñas, M., Carvalho, A.M., I.C.F.R. Ferreira and C. Santos-Buelga,
456 Food Chem. Toxicol., 2012, 50, 1576-1582.
- 457 26 A.R. Hraš, M. Hadolin, Ž. Knez and D. Bauman, Food Chem., 2000, 71, 229-233.
- 458 27 H. Kim, S. Baea, Y. Kima, C-H. Cho, S.J. Kim, Y-J. Kim, S-P. Lee, H-R Kim, Y-I.
459 Hwang, J.S. Kanga and W.J. Lee, Free Radic. Biol. Med., 2013, 65, 573–583.
- 460 28 H-C. Fang, C-L. Chen, P-T. Lee, C-Y. Hsu, C-J. Tseng, P-J. Lu, S-L. Lai, H-M.
461 Chung and K-J. Chou, Food Chem. Toxicol., 2007, 45, 1764-1769.
- 462 29 F. Ferreres, A. Gil-Izquierdo, P.B. Andrade, P. Valentão and F.A. Tomás-Barberán,
463 J., Chromatogr. A, 2007, 1161, 214-223.
- 464 30 F. Cuyckens and M. Claeys, J. Mass Spectrom., 2004, 39, 1-15.
- 465 31 F. Ferreres, B.M. Silva, P.B. Andrade, R.M. Seabra and M.A. Ferreira, Phytochem.
466 Anal., 2003, 14, 352-390.
- 467 32 A.R. Rechner, G. Kuhnle, P. Bremner, G.P. Hubbard, K.P. Moore, C.A. Rice-
468 Evans. Free Rad. Biol. Med., 2002, 33, 220-235.
- 469 33 B. Choque, D. Catheline, V. Rioux and P. Legrand, Biochimie, 2014, 96, 14-21.
- 470 34 J. Whelan, Prostag. Leukotr. Ess., 2008, 79, 165–167.
- 471 35 B. Halliwell, Trends Biochem. Sci., 1999, 24, 255-259.
- 472 36 V.E. Kagan, A.I. Kuzmenkoa, A.A. Shvedovae, E.R. Kisine, R. Lia, I. Martina, P.J.
473 Quinna, V.A. Tyurina, Y.Y. Tyurinaa and J.C. Yalowich, Biochim. et Biophys.
474 Acta, 2003, 1620, 72-84.

Table 1. Bioactivity of *Arenaria montana* methanolic and aqueous extracts.

	Methanolic extract	Aqueous extract	Positive control*
Antioxidant activity			
DPPH scavenging activity (EC ₅₀ , mg/mL)	0.90 ± 0.01 ^a	0.93 ± 0.02 ^a	0.04 ± 0.00
Reducing power (EC ₅₀ , mg/mL)	0.82 ± 0.01 ^a	0.77 ± 0.02 ^b	0.03 ± 0.00
β-carotene bleaching inhibition (EC ₅₀ , mg/mL)	6.25 ± 0.31 ^a	1.71 ± 0.02 ^b	0.003 ± 0.00
TBARS inhibition (EC ₅₀ , mg/mL)	0.90 ± 0.08 ^a	0.20 ± 0.02 ^b	0.004 ± 0.00
Cytotoxic activity			
MCF-7 (breast carcinoma) (GI ₅₀ , μg/mL)	>400 ^a	130.05±8.05 ^b	0.91±0.04
NCI-H460 (non-small cell lung cancer) (GI ₅₀ , μg/mL)	>400 ^a	231.08±5.86 ^b	1.42±0.00
HCT-15 (colon carcinoma) (GI ₅₀ , μg/mL)	>400 ^a	183.51±15.54 ^b	1.91±0.06
HeLa (cervical carcinoma) (GI ₅₀ , μg/mL)	329.46±12.46 ^a	80.21±6.29 ^b	1.14±0.21
HepG2 (hepatocellular carcinoma) (GI ₅₀ , μg/mL)	308.68±13.25 ^a	58.57±6.59 ^b	3.22±0.67
Hepatotoxicity PLP2 (GI ₅₀ , μg/mL)	350.25±5.70 ^a	332.18±3.61 ^b	2.06±0.03

*Trolox and ellipticine for antioxidant and cytotoxic activity assays, respectively. EC₅₀ values correspond to the sample concentration achieving 50% of antioxidant activity or 0.5 of absorbance in reducing power assay. GI₅₀ values correspond to the sample concentration achieving 50% of growth inhibition in human tumour cell lines or in liver primary culture PLP2. In each row different letters mean significant differences (p<0.05).

Table 2. Composition in hydrophilic compounds of wild *Arenaria montana*.

Free sugars	g/100 g dw	Organic acids	g/100 g dw
Fructose	5.46 ± 0.53	Oxalic acid	1.93 ± 0.09
Glucose	2.05 ± 0.33	Quinic acid	0.06 ± 0.00
Sucrose	1.41 ± 0.32	Malic acid	1.48 ± 0.00
Trehalose	0.80 ± 0.01	Ascorbic acid	0.02 ± 0.00
Raffinose	0.43 ± 0.00	Citric acid	0.30 ± 0.03
Total sugars	10.15 ± 0.99	Succinic acid	0.28 ± 0.03
		Fumaric acid	0.01 ± 0.00
		Total organic acids	4.07 ± 0.08

dw- dry weight.

Table 3. Retention time (Rt), wavelengths of maximum absorption in the UV-vis region (λ_{\max}), pseudomolecular and MS² fragment ions (in brackets, relative abundances), tentative identification and quantification of phenolic compounds in wild *Arenaria montana*.

Peak	Rt (min)	λ_{\max} (nm)	Molecular ion [M-H] ⁻ (<i>m/z</i>)	MS ² (<i>m/z</i>)	Tentative identification	Quantification (mg/100 g dw)
1	14.7	330	593	473(4),353(6),341(19),311(65),283(12)	Apigenin 6- <i>C</i> -hexoside-8- <i>C</i> -hexoside	8.71 ± 0.32
2	15.4	336	563	443(29),383(33),353(34),311(4),297(6)	Apigenin 6- <i>C</i> -hexoside-8- <i>C</i> -pentoside	41.63 ± 0.27
3	16.9	350	447	429(12),357(50),327(58),285(12)	Luteolin-6- <i>C</i> -glucoside	22.57 ± 0.84
4	18.7	338	563	443(7),413(62),341(22),311(22),293(72)	Apigenin 2''- <i>O</i> -pentosyl-6- <i>C</i> -hexoside	123.74 ± 2.13
5	18.9	348	785	665(11),609(12),489(4),429(26),339(8),285(4)	Luteolin 2''- <i>O</i> -feruloylhexosyl-6- <i>C</i> -hexoside	37.95 ± 0.50
6	20.1	336	431	341(72),311(100)	Apigenin-6- <i>C</i> -glucoside	159.91 ± 1.83
7	21.6	336	605	563(4),431(6),413(44),341(13),311(13)	Apigenin 2''- <i>O</i> -acetylpentosyl-6- <i>C</i> -hexoside	179.84 ± 0.88
8	22.9	350	635	593(4),515(7),461(5),443(50),371(19),323(68)	Methyl-luteolin 2''- <i>O</i> -acetylpentosyl- <i>C</i> -hexoside	88.36 ± 1.44
9	23.2	330	799	679(7),623(21),443(64),371(6),323(33)	Methyl-luteolin 2''- <i>O</i> -feruloylhexosyl- <i>C</i> -hexoside	450.26 ± 3.50
10	23.6	332	769	649(14),593(19),443(18),413(60),341(7),311(5)	Apigenin 2''- <i>O</i> -feruloylhexosyl-6- <i>C</i> -hexoside	91.68 ± 2.54
Total Flavones						1204.63 ± 5.76

Table 4. Chemical composition in lipophilic compounds of wild *Arenaria montana*.

Fatty acids	Relative percentage	Fatty acids	Relative percentage
C6:0	1.32 ± 0.01	C18:3n3	15.94 ± 0.14
C8:0	0.30 ± 0.01	C20:0	3.84 ± 0.67
C10:0	0.12 ± 0.03	C20:1	0.52 ± 0.29
C12:0	0.66 ± 0.21	C20:2	0.70 ± 0.09
C13:0	0.15 ± 0.00	C20:3n6	1.99 ± 0.04
C14:0	1.37 ± 0.27	C20:4n6	1.75 ± 0.06
C14:1	0.55 ± 0.04	C20:3n3+C21:0	0.50 ± 0.00
C15:0	0.93 ± 0.17	C20:5n3	0.31 ± 0.08
C15:1	0.09 ± 0.00	C22:0	3.58 ± 0.23
C16:0	22.18 ± 0.40	C22:1n9	0.08 ± 0.00
C16:1	0.36 ± 0.18	C23:0	0.20 ± 0.06
C17:0	0.68 ± 0.03	C24:0	3.45 ± 0.46
C18:0	4.38 ± 0.10	SFA	43.16 ± 0.38
C18:1n9	8.57 ± 0.28	MUFA	10.16 ± 0.43
C18:2n6	23.39 ± 0.66	PUFA	46.68 ± 0.82
C18:3n6	2.11 ± 0.02		
<hr/>			
Tocopherols	mg/100 g dw		
α -tocopherol	1.22 ± 0.21		
γ -tocopherol	0.23 ± 0.02		
δ -tocopherol	0.84 ± 0.08		
Total tocopherols	2.29 ± 0.31		

dw- dry weight. SFA- Saturated fatty acids; MUFA- Monounsaturated fatty acids; PUFA- Polyunsaturated fatty acids.




Figure 1. HPLC phenolic profile of wild *Arenaria montana*, obtained at 370 nm.





Figure 2. Fragmentation of α -glycosyl-C-glycosylflavones (adapted from Ferreres et al.²⁹).

TOC graphic

Bioactivity and phytochemical characterization of *Arenaria montana* L.

Eliana Pereira, Lillian Barros, Ricardo C. Calhelha, Montserrat Dueñas, Ana Maria Carvalho, Celestino Santos-Buelga, Isabel C.F.R. Ferreira



Aqueous extract of *A. montana* may be used as a functional food due to the high antioxidant and cytotoxic activity, and to the presence of bioactive compounds.